Truist Securities has downgraded Incyte Company INCY, noting Jakafi’s (ruxolitinib) patent loss approaching in 2028.
Jakafi is Incyte’s top-selling drug. It’s indicated for polycythemia vera in adults, intermediate or high-risk myelofibrosis in adults, and steroid-refractory acute graft versus host illness in grownup and pediatric sufferers.
In second quarter 2024, the drug generated gross sales of $705.9 million, +3% year-over-year, pushed by a 9% enhance in paid demand.
The analyst downgraded the inventory from Purchase to Maintain, with a value goal of $74, down from $83.
Additionally Learn: Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Information From Late-Stage Examine.
With Jakafi’s lack of exclusivity approaching, a key concern is whether or not Incyte’s pipeline in immunology, irritation (I&I), and oncology can compensate for the income decline anticipated from generic competitors. Whereas there may be long-term progress potential within the firm’s pipeline—supported by sturdy Section 2 knowledge and alternatives for enlargement into new indications or mixture therapies—the problem of mitigating the patent cliff stays important.
Moreover, Incyte faces intense competitors, significantly in bigger markets the place it goals to determine a foothold, reminiscent of I&I and stable tumors.
Truist emphasizes the importance of the late-stage outcomes for Povorcitinib in hidradenitis suppurativa (HS), anticipated within the first half of 2025, as a key issue more likely to affect inventory efficiency over the following 12 months.
Moreover, the analyst attracts consideration to the earlier-stage outcomes anticipated within the second half of 2024 for Zilurgisertib in myelofibrosis. Nevertheless, as a result of Novartis AG’s NVS delays and the challenges, mixed with the early growth stage of Incyte’s packages, Truist is adopting a extra cautious stance.
Value Motion: INCY inventory is down 0.93% at $65.81 eventually test Wednesday.
Learn Subsequent:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
